Organon & (US:OGN) GlobeNewswire News Room·2025-07-16 20:01Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Organon securities is from November 3, 2022, to April 30, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]. Group 3: Case Allegations - The lawsuit alleges that Organon made false or misleading statements regarding the sales growth of its product Nexplanon, which was not on track to reach $1 billion by the end of fiscal year 2025 [4]. - It is claimed that Organon was unlikely to achieve the $1 billion milestone payment from Merck & Co. related to Nexplanon sales [4]. - The lawsuit suggests that Organon was not on track to maintain its required free cash flow of $1 billion to sustain its dividend and might face challenges in maintaining its corporate debt ratings [4].